Assembly Biosciences, Inc. (ASMB) stock
ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.50+1.21 (+5.68%)
Close on Nov 17, 2026Market cap $458.11MP/E –Yield –
Assembly Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Assembly Biosciences's ebitda for the twelve months ending Jun 30, 2026 was -$8.69M. For fiscal 2025 it was -$11.99M. The highest annual figure on record is -$11.99M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.99M | – |
| FY2024 | Dec 31, 2024 | -$45.29M | – |
| FY2023 | Dec 31, 2023 | -$64.20M | – |
| FY2022 | Dec 31, 2022 | -$93.62M | – |
| FY2021 | Dec 31, 2021 | -$132.22M | – |
| FY2020 | Dec 31, 2020 | -$64.09M | – |
| FY2019 | Dec 31, 2019 | -$102.22M | – |
| FY2018 | Dec 31, 2018 | -$92.09M | – |
| FY2017 | Dec 31, 2017 | -$52.01M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.34M | – |
| Q4 FY2025 | Dec 31, 2025 | $19.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.50M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.92M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.70M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.27M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$62.77M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.76M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.55M | -451.4% |
| Q1 FY2021 | Mar 31, 2021 | -$27.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$39.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.88M | – |
| Q2 FY2020 | Jun 30, 2020 | $6.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.58M | – |
| Q4 FY2019 | Dec 31, 2019 | -$28.57M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.88M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$28.20M | – |
| Q4 FY2018 | Dec 31, 2018 | -$26.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.41M | – |
| Q2 FY2018 | Jun 30, 2018 | -$27.02M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.50M | – |
See a number that looks wrong?